Limits to genetic intervention in humans: somatic and germline

Area of Science:

• Biotechnology
• Medical Ethics
• Human Genetics

Background:

• Somatic cell gene therapy shows promise for specific monogenic hereditary defects.
• Ethical considerations arise with potential enhancements beyond disease correction.
• Germline cell gene alteration is feasible in animals but raises significant human ethical concerns.

Purpose of the Study:

• To evaluate the potential and ethical implications of somatic and germline gene therapies.
• To discuss the limitations and risks associated with genetic interventions.
• To explore alternative approaches like prenatal diagnosis.

Main Methods:

• Conceptual analysis of gene therapy applications.
• Ethical framework evaluation for somatic versus germline interventions.
• Review of current genetic technologies and their limitations.

Main Results:

• Somatic gene therapy is primarily suited for monogenic defects, with minimal ethical issues.
• Germline gene therapy in humans is ethically problematic due to risks to future generations and potential for unintended consequences.
• Complex traits are unlikely to be modified effectively by current gene therapy techniques.
• Prenatal diagnosis and selective abortion offer a safer alternative for many genetic conditions.

Conclusions:

• Somatic gene therapy has a narrow but ethically manageable scope.
• Germline gene therapy presents substantial risks and ethical objections, with alternatives often being more practical.
• The complexity of polygenic traits limits the near-term utility of gene editing for enhancement.
• Public apprehension regarding human 'blueprinting' fuels anti-science sentiments.